The Botox Brow Lift: The Millimetre or Two a Neurotoxin Can Actually Raise a Brow, the Muscle Balance That Decides Whether It Lifts or Drops, and the Eye Drops Every Injector Should Keep on the Shelf

Nobody walks into an injector's office asking for a Botox brow lift. They walk in saying their eyes look tired, or that their upper lids have started to feel heavy, or that the outer corner of the brow has slid down far enough that eyeshadow no longer has a place to go. What they are offered, quite often, is a few units of neurotoxin placed in a pattern that is meant to raise the brow, and the thing has acquired a name, the chemical brow lift, that suggests something more decisive than what it is.

What it is, is a rebalancing. The brow sits where it sits because a single muscle pulls it up and four muscles pull it down, and the resting position is the truce between them. Weaken the ones that pull down and the one that pulls up gains a little ground. The lift that results is real, it is measurable, and it is small: the studies that bothered to put a ruler to it found one to a few millimetres, depending on where along the brow you measure and which muscles were treated. Whether a millimetre or three is worth the appointment depends entirely on the face it is done to, and that is the part of the conversation that gets skipped.

This piece is the non-surgical companion to the piece on the lateral brow lift and the forehead lift, which covered the operations. It is also, in a sense, the other half of the piece on why Botox stops working, because the brow is where a neurotoxin's limits show most clearly. It can move a brow. It cannot move it far, it cannot move it for long, and on a certain kind of face it moves it the wrong way.

What a chemical brow lift actually does

The short answer: a Botox brow lift weakens the muscles that pull the brow downward, chiefly the tail of the orbicularis oculi around the eye and the corrugator, procerus, and depressor supercilii between the brows, so that the frontalis, the only muscle that raises the brow, is left pulling against less resistance; every neurotoxin used this way is used off-label, because no product is approved to lift a brow.

The anatomy is simple enough to draw on a napkin. The frontalis is the flat sheet of muscle across the forehead. It is the elevator, and it is the only one: nothing else on the face lifts the brow. Working against it are the depressors. Between the brows sit the corrugator supercilii, which pulls the brow inward and down and makes the vertical frown lines, the procerus, which pulls the centre down and makes the horizontal line at the root of the nose, and the small depressor supercilii beneath the inner brow. Around the eye, the orbicularis oculi, the ring muscle that closes the lids, has an outer portion that runs beneath the tail of the brow and pulls it down every time the eye squints or smiles.

Weaken the depressors and the brow rises, because the frontalis was already pulling and now pulls unopposed. The classic pattern treats the glabellar complex in the centre, which is the FDA-approved indication for every neurotoxin on the market and happens to lift the inner and middle brow as a side effect, and adds a few units into the outer orbicularis beneath the brow's tail, which lifts the outer third. That lateral injection is the one that turns a routine glabellar treatment into a brow lift, and it is the one that is entirely off-label.

Off-label matters here for a specific reason. OnabotulinumtoxinA, the product sold as Botox, carries Food and Drug Administration approval for the glabellar lines, granted in 2002, for the lateral canthal lines, in 2013, and for the horizontal forehead lines, in 2017. Brow elevation is on none of the labels. The piece on neurotoxin brands explains that the other products carry similar but narrower approvals. An off-label use is legal and, in this case, well described in the literature, but it means the dose, the placement, and the technique are the injector's own, and the piece on who is injecting you is where the reader should go if the person holding the syringe learned the pattern from a weekend course.

The one thing the injection does not touch is the frontalis, or at least it should not touch the lower half of it. This is the distinction that separates a brow lift from a forehead treatment, and it is where most of the trouble in this piece comes from.

• The glabellar injections (corrugators, procerus) lift the inner and middle brow by a small amount and are the part of the treatment most patients have already had for their frown lines.
• The lateral orbicularis injection, two to four units per side placed just below the tail of the brow, is the part that lifts the outer brow and gives the treatment its name.
• The frontalis is the elevator. Treat it high, and the forehead lines soften while the brow position is mostly preserved. Treat it low, or heavily, and the brow drops, because the only muscle that could hold it up has been switched off.

How much lift, measured: the millimetre reality

The short answer: the published measurements put the brow elevation from neurotoxin at roughly one millimetre at the centre of the brow after a glabellar treatment and up to a few millimetres at the outer tail after the lateral orbicularis is added, which is enough to open a mildly hooded eye and not enough to correct a brow that has genuinely fallen.

The literature on this is older than most patients would guess. In 1999 Huilgol, Carruthers, and Carruthers published a study in Dermatologic Surgery under the title "Raising eyebrows with botulinum toxin," in which they treated the glabellar complex and measured the brow before and after. The brow went up. The amount was about a millimetre at the middle of the brow, with more variation at the inner end, and the effect was an incidental gain from treating frown lines rather than a procedure in its own right. A year later, in 2000, Ahn, Catten, and Maas published "Temporal brow lift using botulinum toxin A" in Plastic and Reconstructive Surgery, treating the lateral orbicularis beneath the brow tail in a series of patients and measuring at the lateral canthus. The outer brow rose by a few millimetres on average. Their conclusion was that the lift was real and reproducible, and that it was lateral, which is where most brows fall first.

The Carruthers group returned to the question in 2007 in the same journal, treating the glabella at a range of doses and measuring brow height at three points. Higher glabellar doses produced more elevation at the inner and middle brow, again in the range of one to a few millimetres, and the finding that matters for patients is that the lift was measurable at every dose and dramatic at none.

A few millimetres sounds like nothing, and in most parts of the face it would be. At the brow it is not, for a reason of proportion: the distance between the brow and the lash line on a young adult is only about a centimetre and a half at the centre, less at the sides. Raising the tail two millimetres is a meaningful fraction of the space the eye has to work with, and a patient whose upper lid was being crowded by a brow that had drifted down will notice the difference in the mirror. What they will not get is a change visible from across a room, and an injector who promises the look of a surgical lift from a syringe is selling something the studies do not support.

The other number is duration, and it is the same as for any neurotoxin: the effect peaks at about two weeks, holds for two to three months, and is gone by four. The piece on how long results last covers the general arithmetic. For the brow specifically it means that a patient who likes the result is buying three or four appointments a year, and that the cumulative cost across a decade will exceed a surgical lift by a wide margin, which is not an argument against it, only a fact that belongs in the conversation.

"

A neurotoxin does not lift a brow. It weakens the muscles that hold the brow down and lets the one muscle that holds it up win by a millimetre or three. On a face where the elevator is strong and the lids are merely crowded, that is enough. On a face where the elevator is already working overtime to keep the eyes open, switching off the wrong muscle drops everything.

"

Who gets a lift and who gets a drop

The short answer: the treatment works on a patient with a mild lateral hooding, a strong frontalis, and upper lids that are crowded rather than drooping; it fails, or reverses, on the patient whose forehead is already contracting all day to hold up a fallen brow or a weak lid, because that patient's frontalis is the only thing keeping the eyes open and any treatment that touches it, or any lift that removes the reason for it, drops the brow.

The examination that sorts the two takes thirty seconds and is skipped more often than it should be. The injector asks the patient to close their eyes gently, relax the forehead completely, and then open the eyes without raising the brows. Some patients cannot do it: the moment the eyes open the forehead lines reappear and the brows go up, because the frontalis has been recruited, for years, to compensate for a brow that has descended or an upper lid that no longer lifts fully on its own. That patient is a compensator. Their resting brow position, the one the frontalis is hiding, is low, and their forehead lines are the price they pay for seeing properly.

Treat that patient's forehead lines and the compensation is removed. The brow falls to where it was actually sitting, the upper lid follows it, the eye looks smaller and heavier, and the patient returns at two weeks asking what went wrong. Nothing went wrong with the toxin; the wrong muscle was treated. This is the most common bad outcome in forehead injecting and it is entirely predictable from the examination. The piece on eyelid ptosis versus blepharoplasty covers the parallel problem in surgery, where an operation that removes lid skin without addressing a weak levator muscle leaves the patient no better, and the same logic applies: find out what is holding the eye open before you switch anything off.

The compensator is also the patient who benefits least from the lateral lift, because a brow that has genuinely descended, with the tail resting on the orbital rim, will not be moved back to where it belongs by a couple of millimetres. What they need is the operation, and a candid injector says so and refers to the lateral brow lift piece rather than the appointment book.

The good candidate is, by contrast, the patient in their thirties or forties whose brow is still where it should be but whose tail has begun to soften, whose upper lid has started to look heavy at the end of the day, who has no difficulty opening their eyes with a relaxed forehead, and who would like the outer eye opened a little without an incision. On that face the lateral injection does what it is meant to do, the glabellar injection adds a little in the centre, and a small dose high on the forehead, well above the brow, can soften the horizontal lines without dropping anything. The piece on blepharoplasty is worth reading alongside, because the other thing that makes an upper lid look heavy is lid skin itself, which no neurotoxin will remove, and a patient with true dermatochalasis who is offered a brow lift instead is being offered the wrong thing.

There is a further group, which the piece on the fox-eye canthoplasty touched on: the young patient with no hooding at all who wants a lifted, elongated outer eye as a look. The lateral injection will give a slight version of it, safely and temporarily, and it is the sensible thing to try before any of the surgical or thread versions of the same idea. It will not give the exaggerated version, and the patient who wants that should be told what they are actually asking for.

The injection map and what goes wrong

The short answer: the treatment goes wrong in three recognisable ways, the peaked outer brow that follows over-treating the centre of the forehead while leaving the outer frontalis working, the dropped brow that follows treating the frontalis too low or too heavily, and the dropped eyelid that follows toxin reaching the levator muscle inside the orbit; the first two are corrected with a few more units, the third is temporary and can be eased with prescription eye drops.

The peaked brow has a name in the trade, usually the Spock brow or the Mephisto sign, and a cause that is easy to understand once the anatomy is clear. If the central frontalis is treated and the outer frontalis is not, the untreated outer portion keeps pulling while the centre goes slack, and the brow rises at the tail into a sharp arch that reads as surprise or menace. It is the commonest complaint after a forehead treatment, it appears at about two weeks when the toxin is fully active, and the fix is two or three units placed into the outer frontalis above the peak, which lets the tail settle. It is also avoidable, by treating the frontalis evenly across its width or, on a patient who wants a lift, by not treating it at all.

The dropped brow is the compensator's problem described above, and it also happens to non-compensators when the frontalis is injected in its lower half. Most injectors keep forehead injections at least two centimetres above the brow, and higher on a patient with a short forehead, precisely to leave the lower frontalis working. There is no reversal for it. The toxin wears off in three to four months, and until then the only help is a small additional dose into the depressors, which gives back a millimetre of what was lost.

The dropped eyelid is the complication that worries injectors, and it is different in kind. It happens when toxin placed near the brow diffuses through the orbital septum to the levator palpebrae superioris, the muscle that raises the upper lid, and it produces a lid that hangs a millimetre or two lower on the treated side, usually appearing within a week or two and lasting anywhere from a few weeks to the full duration of the toxin. Its published incidence after glabellar treatment is low, a few percent in the early trials and lower in experienced hands, and it is more likely when injections are placed close to the orbital rim, when large volumes are used, or when the area is massaged afterward. The piece on Botox and filler in one visit explains why the two are usually done in a particular order, and part of the reason is that pressure on a freshly injected glabella is one of the things that can push toxin where it should not go.

Two prescription eye drops treat it, and this is the detail that separates the injector who has planned for the complication from the one who has only read about it. Apraclonidine 0.5 percent, a glaucoma drop, stimulates the small Müller's muscle in the upper lid and lifts it a millimetre or two for a few hours per dose; it has been the standard off-label answer for twenty years. Oxymetazoline 0.1 percent, sold as Upneeq, was approved by the FDA in 2020 for acquired blepharoptosis and works the same way with a longer effect. Neither shortens the toxin; both make the wait tolerable. An injector who does not know what apraclonidine is should not be injecting near an eye.

The remaining complications are the ordinary ones. Bruising is common, especially at the lateral orbicularis site where the skin is thin, and the piece on arnica and bromelain covers what does and does not help. Headache for a day or two is common after glabellar treatment. Asymmetry between the two brows at two weeks is common and is corrected with a unit or two on the lower side, which is why every reputable practice books a two-week review and why the piece on injectables before a big event says to have the treatment a month out rather than a week.

Where it sits against surgery, threads, ultrasound, and filler

The short answer: the neurotoxin lift is the smallest, cheapest, safest, and shortest-lived of the options for a heavy outer eye, and it is the right first step for a patient with mild hooding and a strong forehead; the surgical lateral brow lift is the only option that moves a genuinely fallen brow and holds it there, and the threads, energy devices, and filler that occupy the space between the two deliver, in the published evidence, less than their marketing and more than nothing.

The comparison is worth laying out plainly because the alternatives are sold side by side, often in the same clinic, and the patient is rarely told how they rank.

• The surgical lateral brow lift and the endoscopic brow lift move the brow by the amount the surgeon chooses, hold it for years, and can be tailored to the tail alone. They involve incisions in the hairline, a general anesthetic or heavy sedation, two weeks of visible recovery, and a real if small risk to the frontal branch of the facial nerve, which the piece on facial nerve injury describes. The endoscopic facelift piece covers why the endoscopic version fell out of favour and returned. For a brow that has actually fallen, this is the answer, and no injection substitutes for it.
• Thread lifts to the brow use barbed absorbable sutures passed under the skin from the hairline to hook and pull the tail upward. The piece on PDO thread lifts reviewed the evidence and found that the lift is real for a few months and mostly gone within a year, with visible or palpable threads, dimpling, and asymmetry as the recognised problems. At the brow specifically the thin skin makes visibility more likely.
• Microfocused ultrasound, sold as Ultherapy, holds an FDA clearance from 2009 for lifting the brow, which makes it the only non-surgical device with the word "lift" on its label. The clearance was granted on a study showing an average brow elevation of a little under two millimetres at ninety days in about six in ten patients, which places it in the same range as the neurotoxin, at ten to twenty times the price per session and with the tenderness and occasional nerve irritation the energy-based skin tightening piece describes. It lasts longer than toxin, perhaps a year, and it is a reasonable choice for a patient who wants the small lift without a syringe every three months.
• Filler does not lift the brow, but placed in a hollow temple it supports the tail and can make a brow that has fallen into a temporal hollow look higher, which the piece on filler for hollow temples covers. Placed under the brow itself, in small amounts, it can restore the fullness that a deflated brow loses with age. It is a volume answer to what is sometimes a volume problem, and it combines well with the toxin.

The honest ordering, for a patient with mild hooding, is toxin first, because it is cheap and reversible and shows the patient whether a lift of a few millimetres is what they wanted at all. A patient who likes the result can stay on it, add temple filler if the tail is hollow, and consider ultrasound if they want the same lift with fewer visits. A patient who liked it but wanted more has learned something valuable: that the direction is right and the amount is not, and that the next step is the consultation the second consultation piece describes, with a surgeon who does brow lifts. A patient on whom the toxin dropped the brow has learned the most valuable thing of all, that they were a compensator, and that the operation, not the injection, was always the answer.

The last point is about the marketing. The piece on trademarked procedure names covered the general habit of dressing an ordinary treatment in a proprietary name, and the brow is a case in point: the "Botox brow lift," the "chemical brow lift," and the "non-surgical brow lift" are the same eight to twelve units in the same two or three places, and a clinic that charges more for the name than for the units is charging for the name. The piece on how to avoid looking fake is the other reference worth carrying in, because the over-lifted brow, the arch that reads as permanent surprise, is one of the most recognisable signs of work on a face, and the right dose here is the one that nobody notices.

The honest summary

The Botox brow lift is a rebalancing of the muscles around the brow, not a lift in the surgical sense. It weakens the depressors, chiefly the outer orbicularis beneath the brow's tail and the frown muscles between the brows, so that the frontalis, the only elevator, gains a little ground. The published studies measured that ground at about a millimetre in the centre and up to a few millimetres at the tail. It is enough to open a mildly hooded outer eye on a patient in their thirties or forties whose forehead is not already working to hold their eyes open. It is not enough to correct a brow that has fallen, and it does nothing for lid skin.

Every neurotoxin used for this purpose is used off-label. That is legal and well described, and it means the injector's judgment is the whole procedure. The judgment that matters most is the thirty-second examination that identifies the compensator, the patient whose forehead lines exist because their frontalis is propping up a low brow or a weak lid. Treat that patient's forehead and the brow drops. Treat the wrong part of any patient's forehead and the brow drops or peaks. Let toxin reach the levator and the lid drops. The first two are fixed with a few more units at the two-week review; the third is fixed by time, and eased by apraclonidine or Upneeq, which an injector working near the eye should stock.

Against the alternatives, the toxin is the smallest, cheapest, and safest step and the right first one for the right patient. Ultrasound gives a similar lift for longer at a much higher price. Threads give a short lift with their own problems. Filler supports a hollow temple but does not lift. The surgical lateral brow lift is the only thing that moves a fallen brow and keeps it there, and a patient who tried the toxin and wanted more has learned, cheaply, that surgery was the answer. Ask which muscles are being treated and at what dose, ask whether you were examined with your forehead relaxed, and ask what the plan is if your eyelid droops. The injector who answers all three without looking anything up is the one to book.